A novel, patient-tailored monoclonal antibody therapy has shown promise in treating moderate to severe atopic dermatitis. Patients who participated in a clinical trial of rocatinlimab showed positive results while taking the drug and up to 20 weeks after stopping therapy, Mount Sinai researchers have reported in The Lancet. The researchers said the results indicate that […]